Recruiting
Phase 2

STIMULAN VG vs. SoC

Sponsor:

Biocomposites Ltd

Code:

NCT06283979

Conditions

Pressure Ulcer, Stage IV

Osteomyelitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

STIMULAN VG

Standard of Care

Study Details

Brief summary:

The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.

Conditions

Pressure Ulcer, Stage IV

Osteomyelitis

Study ID

NCT06283979

Start date

Jun 15, 2025

Status verified date

Oct, 2025

Completion date

Dec 1, 2026

Anticipated

Primary completion date

Dec 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

In order to be eligible to participate in this study, subjects must meet all of the following criteria:

1. Presenting with a Stage IV pressure ulcer requiring treatment of excision, bony debridement and flap coverage/primary closure.
2. Operative candidate for flap surgery or primary closure.
3. Presence of focal osteomyelitis as suggested by imaging to show extent of infection. Acceptable imaging techniques are Magnetic Resonance Imaging or CT scan.
4. Adults ≥ 18 years in age at the time of treatment.
5. Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.
6. Ability of the subject or legal authorized representative to provide voluntary, signed and dated informed consent prior to any study-related procedures.

Subjects who meet any of the following criteria will be excluded from participating in this study:

1. Reasons contributing to pressure ulcer cannot be addressed.
2. Severe immunological compromised patients as determined by the clinician.
3. Patients with diffuse or widespread pelvic osteomyelitis that is not amenable to adequate margins for debridement.
4. Patients presenting with head pressure ulcers.
5. Current or recent history (within last 2 years) of active substance abuse (e.g., recreational drugs, narcotics, or alcohol) that in the judgement of the investigator, may compromise the participant's safety/recovery or ability to follow the trial procedures.
6. Current smoker.
7. Diabetic patient with Hba1C level above 9.
8. Allergy to any component of the investigational product, such as calcium sulfate, glycopeptide antibiotics (Vancomycin), or aminoglycoside antibiotics (Gentamicin).
9. Concurrent involvement in a study of another investigational product.
10. Pregnant or planning to become pregnant during study period.
11. Flexion contractures where patient cannot passively get full extension.
12. Uncontrolled muscle spasms.
13. Unable to comply with bedrest restriction or offloading requirements
14. Unable to provide consent.
15. Fecal or urinary incontinence with contamination of the wound.
16. Lower extremity pressure ulcer location that is vascularly compromised as defined by an Ankle Brachial Index ≤ 0.7 mm Hg OR toe brachial index ≤ 0.6 mm OR toe pressure ≤ 40 mm Hg OR transcutaneous oximetry ≤ 40 mm Hg \*
17. Investigator considers the participant to be clinically malnourished.
18. Any conditions with known hypercalcemia (> 10.3 mg/dl) or posing a significant risk for developing hypercalcemia (i.e., Hyperparathyroidism).
19. Investigator believes trial participation may compromise safety of the participant or trial results.

  • Patients presenting with lower extremity pressure ulcers that are vascularly compromised can be rescreened followed successful revascularization

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Interventional STIMULAN VG

Ulcer bursectomy and debridement and STIMULAN VG insertion into the ulcer cavity.

Flap/primary closure. Peri-operative antibiotics.

active comparator: Standard of Care (SoC)

Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.

Interventions

STIMULAN VG

Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure.

Standard of Care

Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.

Primary outcome measure

  • Individual patient success and findings at the 8 week follow-up visit [ Time Frame: 8 week ]

Central Contacts and Locations

Central contacts

Keira Watts, Clinical Research Director

+44 (0) 1782 338 580clinicaltrials@biocomposites.com

Daniel Roberts

droberts@mcra.com

Locations

Advanced Foot Care, LLC

Recruiting

Phoenix, Arizona, United States, 85032

Contacts

Principal Investigator:

Jaminelli Banks, DPM

Northwestern University Feinberg School of Medicine

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Principal Investigator:

Robert Galiano, MD

Henry Ford Hospital

Recruiting

Detroit, Michigan, United States, 48202

Contacts

Sarah Meehan

smeehan1@hfhs.org

Principal Investigator:

Aamir Siddiqui, MD

University of Mississippi Medical Center

Recruiting

Jackson, Mississippi, United States, 39216

Contacts

Venkata Seerapu

vseerapu@umc.edu

Laxmi Dhungel

idhungel@umc.edu

Principal Investigator:

Ian Hoppe, MD

Missouri Orthopaedic Institute

Recruiting

Columbia, Missouri, United States, 65201

Contacts

Principal Investigator:

Brett Crist, MD

University of Nebraska Medical Center

Recruiting

Omaha, Nebraska, United States, 68198

Contacts

Principal Investigator:

James Willcockson, MD

Rutgers New Jersey Medical School

Recruiting

Newark, New Jersey, United States, 07103

Contacts

Principal Investigator:

Alex Wong, MD, FACS

NYU Langone Hospital - Long Island Clinical Research Center

Recruiting

Mineola, New York, United States, 11501

Contacts

Principal Investigator:

Scott Gorenstein, MD

University of Pittsburgh, McGowan Institute for Regenerative Medicine

Recruiting

Pittsburgh, Pennsylvania, United States, 15219

Contacts

Principal Investigator:

Sashwati Roy, PhD, MS

More Information

Sponsor

Biocomposites Ltd

Last update posted

May 6, 2026

Last verified

Oct, 2025

Keywords

  • between-group effect size
  • surgical debridement
  • ulcer bursectomy
  • systemic antibiotics

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Biocomposites Ltd on 2026-05-06.